A Phase II Trial of Continuous Low-Dose Temozolomide for Patients With Recurrent Malignant Glioma.
Phase of Trial: Phase II
Latest Information Update: 03 Mar 2016
At a glance
- Drugs Temozolomide (Primary)
- Indications Glioblastoma; Glioma
- Focus Therapeutic Use
- 17 Dec 2013 Status changed from active, no longer recruiting to completed as per ClinicalTrials.gov record.
- 04 Mar 2013 Additional lead trial centre identified as reported by ClinicalTrials.gov.
- 04 Mar 2013 Planned End Date changed from 1 Dec 2010 to 1 Dec 2014 as reported by ClinicalTrials.gov.